
Pregabalin Market by Dosage Forms (Extended Release, Oral Capsule, Oral Solution), Drug Class (Anticonvulsants, Fibromyalgia Agents), Application, End-Users, Distribution Channel - Global Forecast 2024-2030
Description
Pregabalin Market by Dosage Forms (Extended Release, Oral Capsule, Oral Solution), Drug Class (Anticonvulsants, Fibromyalgia Agents), Application, End-Users, Distribution Channel - Global Forecast 2024-2030
The Pregabalin Market size was estimated at USD 1.12 billion in 2023 and expected to reach USD 1.20 billion in 2024, at a CAGR 7.74% to reach USD 1.89 billion by 2030.
Global Pregabalin Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Pregabalin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pregabalin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Pregabalin Market, highlighting leading vendors and their innovative profiles. These include Almelo Private Limited, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, BAL Pharma Ltd., Cipla Limited, Dongbang FTL, Genesis Biotec Inc., Hikal Ltd., Lupin Limited, Medley Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Lifesciences Limited.
Market Segmentation & Coverage
This research report categorizes the Pregabalin Market to forecast the revenues and analyze trends in each of the following sub-markets:
Dosage Forms
Extended Release
Oral Capsule
Oral Solution
Oral Tablet
Drug Class
Anticonvulsants
Fibromyalgia Agents
Application
Anxiety Disorder
Epilepsy
Neuropathic Pain
End-Users
Homecare
Hospitals
Research institute
Specialty Clinics
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Pregabalin Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pregabalin Market?
3. What are the technology trends and regulatory frameworks in the Pregabalin Market?
4. What is the market share of the leading vendors in the Pregabalin Market?
5. Which modes and strategic moves are suitable for entering the Pregabalin Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Pregabalin Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing cases of epilepsy and anxiety disorders
- 5.1.1.2. Favorable government initiatives for raising awareness for anxiety issues
- 5.1.1.3. Rising geriartic population with neuropathic pain
- 5.1.2. Restraints
- 5.1.2.1. Presence of substitutes and lack of awareness
- 5.1.3. Opportunities
- 5.1.3.1. Rising approvals of generic versions of the medicine
- 5.1.3.2. Advancements and product enhancements for pregabalin
- 5.1.4. Challenges
- 5.1.4.1. Adverse effects on health and product recalls
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Pregabalin Market, by Dosage Forms
- 6.1. Introduction
- 6.2. Extended Release
- 6.3. Oral Capsule
- 6.4. Oral Solution
- 6.5. Oral Tablet
- 7. Pregabalin Market, by Drug Class
- 7.1. Introduction
- 7.2. Anticonvulsants
- 7.3. Fibromyalgia Agents
- 8. Pregabalin Market, by Application
- 8.1. Introduction
- 8.2. Anxiety Disorder
- 8.3. Epilepsy
- 8.4. Neuropathic Pain
- 9. Pregabalin Market, by End-Users
- 9.1. Introduction
- 9.2. Homecare
- 9.3. Hospitals
- 9.4. Research institute
- 9.5. Specialty Clinics
- 10. Pregabalin Market, by Distribution Channel
- 10.1. Introduction
- 10.2. Hospital Pharmacy
- 10.3. Online Pharmacy
- 10.4. Retail Pharmacy
- 11. Americas Pregabalin Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Pregabalin Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Pregabalin Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. FPNV Positioning Matrix
- 14.2. Market Share Analysis, By Key Player
- 14.3. Competitive Scenario Analysis, By Key Player
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.1.1. Almelo Private Limited
- 15.1.2. Amneal Pharmaceuticals LLC
- 15.1.3. Aurobindo Pharma Limited
- 15.1.4. BAL Pharma Ltd.
- 15.1.5. Cipla Limited
- 15.1.6. Dongbang FTL
- 15.1.7. Genesis Biotec Inc.
- 15.1.8. Hikal Ltd.
- 15.1.9. Lupin Limited
- 15.1.10. Medley Pharmaceuticals Limited
- 15.1.11. Novartis AG
- 15.1.12. Pfizer Inc.
- 15.1.13. Teva Pharmaceutical Industries Ltd.
- 15.1.14. Torrent Pharmaceuticals Ltd.
- 15.1.15. Zydus Lifesciences Limited
- 15.2. Key Product Portfolio
- 16. Appendix
- 16.1. Discussion Guide
- 16.2. License & Pricing
- FIGURE 1. PREGABALIN MARKET RESEARCH PROCESS
- FIGURE 2. PREGABALIN MARKET SIZE, 2023 VS 2030
- FIGURE 3. PREGABALIN MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PREGABALIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. PREGABALIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. PREGABALIN MARKET DYNAMICS
- FIGURE 7. PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
- FIGURE 8. PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. PREGABALIN MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 10. PREGABALIN MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. PREGABALIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 12. PREGABALIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. PREGABALIN MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 14. PREGABALIN MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 16. PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 20. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. PREGABALIN MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 26. PREGABALIN MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.